[1] |
Reed WB, Walker R, Horowitz R. Cutaneous leiomyomata with uterine leiomyomata[J]. Acta Derm Venereol, 1973, 53(5):409-416.
doi: 10.2340/0001555553409416
|
[2] |
Kiuru M, Launonen V. Hereditary leiomyoma- tosis and renal cell cancer (HLRCC)[J]. Curr Mol Med, 2004, 4:869-875.
doi: 10.2174/1566524043359638
|
[3] |
Yu Y, Zheng M, Zhu W, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): Case series and review of the literature[J]. Urol Oncol, 2021, 39(11):791.e9-791.e16. doi: 10.1016/j.urolonc.2021.07.026.
|
[4] |
Ooi A. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research[J]. Semin Cancer Biol, 2020, 61:158-166. doi: 10.1016/j.semcancer.2019.10.016.
pmid: 31689495
|
[5] |
Gurruchaga Sotés I, Alves AN, Arregui SV, et al. Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)[J]. Curr Oncol, 2021, 28(4):2346-2350. doi: 10.3390/curroncol28040216.
pmid: 34202275
|
[6] |
黄丽璇. 以多发性皮肤平滑肌瘤首诊HLRCC综合征一例[D]. 石家庄: 河北医科大学, 2020.
|
[7] |
Catarina T, Quental MS, Brandão JR, et al. Hereditary Leiomyomatosis and Renal Cell Cancer-Recognizing Patterns May Save Lives[J]. J Kidney Cancer VHL, 2022, 9(2):27-31. doi: 10.15586/jkcvhl.v9i2.222.
pmid: 36118792
|
[8] |
许倩雯, 黄海建, 李柏成, 等. 延胡索酸水合酶缺陷型子宫平滑肌瘤29例临床病理特征[J]. 临床与实验病理学杂志, 2022, 38(3):299-303. doi: 10.13315/j.cnki.cjcep.2022.03.009.
|
[9] |
WHO classification of tumours: female genital tumours[M]. Lyon(France): IARC Publications, 2020:272-279.
|
[10] |
Montironi R, Cimadamore A. Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity[J]. Eur Urol, 2022, 82(5):483-486. doi: 10.1016/j.eururo.2022.07.032.
pmid: 35963651
|
[11] |
El-Zaatari Z, Divatia MK. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma: Morphological appraisal with a comprehensive review of differential diagnoses[J]. Indian J Pathol Microbiol, 2020, 63(Suppl):S7-S17. doi: 10.4103/IJPM.IJPM_877_19.
|
[12] |
Thompson AJ, Alwan YM, Ramani V, et al. Cost-effectiveness model of renal cell carcinoma (RCC) surveillance in hereditary leiomyomatosis and renal cell carcinoma (HLRCC)[J]. J Med Genet, 2023, 60(1):41-47. doi: 10.1136/jmedgenet-2021-108215.
|
[13] |
Ahvenainen T, Kaukomaa J, Kämpjärvi K, et al. Comparison of 2SC, AKR1B10, and FH Antibodies as Potential Biomarkers for FH-deficient Uterine Leiomyomas[J]. Am J Surg Pathol, 2022, 46(4):537-546. doi: 10.1097/PAS.0000000000001826.
|
[14] |
徐亮, 王杜娟, 王雪, 等. 肾集合管癌8例临床病理分析[J]. 临床与实验病理学杂志, 2020, 36(10):1235-1237. doi: 10.13315/j.cnki.cjcep.2020.10.025.
|
[15] |
Rysz J, Franczyk B, Ławiński J, et al. Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC)[J]. Int J Mol Sci, 2021, 23(1):151. doi: 10.3390/ijms23010151.
|
[16] |
吴亚珊. 基于WES测序的SDH缺陷型肾细胞癌的临床病理学及分子特征研究[D]. 乌鲁木齐: 新疆医科大学, 2022.
|
[17] |
王露, 樊月, 王耀辉. 两种酷似乳头状肾细胞癌的少见肾脏肿瘤的临床病理观察[J]. 诊断病理学杂志, 2022, 29(9):793-797. doi: 10.3969/j.issn.1007-8096.2022.09.003.
|
[18] |
Franke K, Vagher J, Boyle J, et al. Rare variant in the fumarate hydratase gene found in patients with clinical features of hereditary leiomyomatosis and renal cell cancer (HLRCC): A case series[J]. Clin Case Rep, 2022, 10(3):e05513. doi: 10.1002/ccr3.5513.
|
[19] |
Chayed Z, Kristensen LK, Ousager LB, et al. Hereditary leiomyomatosis and renal cell carcinoma: a case series and literature review[J]. Orphanet J Rare Dis, 2021, 16(1):34. doi: 10.1186/s13023-020-01653-9.
pmid: 33461594
|
[20] |
Rompre-Brodeur A, Owens-Walton J, Gurram S, et al. Management of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma[J]. J Urol, 2021, 206(Suppl 3):e779. doi:10.1097/JU.0000000000002063.18.
|
[21] |
Choi Y, Keam B, Kim M, et al. Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients[J]. Cancer Res Treat, 2019, 51(4):1549-1556. doi: 10.4143/crt.2019.086.
pmid: 30913859
|
[22] |
Wang T, Huang Y, Huang X, et al. Complete Response of Hereditary Leiomyomatosis and Renal Cell Cancer(HLRCC)-Associated Renal Cell Carcinoma to Pembrolizumab Immunotherapy: A Case Report[J]. Front Oncol, 2021, 11:735077. doi: 10.3389/fonc.2021.735077.
|